SIRS or strong pharmaceutical composition for the virulent influenza infection treatment

摘要

Disclosed are a pharmaceutical composition for treating SIRS and a pharmaceutical composition for treating highly pathogenic influenza, each of which comprises an endothelin activity inhibitor. Preferably, the endothelin activity inhibitor to be used has the following sequence: ALSVD(X)Y(X)AVAS (wherein X represents an amino acid residue), particularly the following sequence: VLNLCALSVDRYRAVASWSRVI-NH2. The pharmaceutical compositions are useful for patients who have developed sepsis or SIRS including sepsis, patients who are in the environments where the development of SIRS is expected, patients who have been infected by highly pathogenic influenza, and patients who are more likely to be infected by highly pathogenic influenza.